Paper17538162
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Siu LL and 13 others. J Clin Oncol, 2007. Cited by 106 papers, by iCite.
Cite this record
ConductScience Library. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. Papers, record 17538162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17538162
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
- PubMed
- Publication types
- Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Cisplatin | Major topic |
| ErbB Receptors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Quinazolines | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Erlotinib Hydrochloride | |
| Female | |
| Humans | |
| Male | |
| Middle Aged |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N01-CM-17107 | NCI NIH HHS | United States | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00030576 | Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Results |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17538157 | Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. | https://conductscience.org/library/papers/17538157 |
Source PubMed
Cited by52
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 106 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40881676 | Unravelling molecular mechanism of oral squamous cell carcinoma and genetic landscape: an insight into disease complexity, available therapies, and future considerations. | Front Immunol | 2025 | https://conductscience.org/library/papers/40881676 | PubMed |
| 40296503 | Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up. | Head Neck | 2025 | https://conductscience.org/library/papers/40296503 | PubMed |
| 39339232 | Exploring the Therapeutic Implications of Co-Targeting the EGFR and Spindle Assembly Checkpoint Pathways in Oral Cancer. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39339232 | PubMed |
| 37844343 | Multi-kinase compensation rescues EGFR knockout in a cell line model of head and neck squamous cell carcinoma. | Arch Oral Biol | 2023 | https://conductscience.org/library/papers/37844343 | PubMed |
| 36646686 | Targeted therapy for head and neck cancer: signaling pathways and clinical studies. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36646686 | PubMed |
| 35453483 | Gb3/cd77 Is a Predictive Marker and Promising Therapeutic Target for Head and Neck Cancer. | Biomedicines | 2022 | https://conductscience.org/library/papers/35453483 | PubMed |
| 34771633 | Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34771633 | PubMed |
| 33335306 | Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. | Oncogene | 2021 | https://conductscience.org/library/papers/33335306 | PubMed |
| 31933185 | Current Prospects of Molecular Therapeutics in Head and Neck Squamous Cell Carcinoma. | Pharmaceut Med | 2019 | https://conductscience.org/library/papers/31933185 | PubMed |
| 29568372 | Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma. | Oncotarget | 2018 | https://conductscience.org/library/papers/29568372 | PubMed |
| 29371473 | Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. | Oncologist | 2018 | https://conductscience.org/library/papers/29371473 | PubMed |
| 29232766 | Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma. | Cell Prolif | 2018 | https://conductscience.org/library/papers/29232766 | PubMed |
| 29113454 | Modulators of Redox Metabolism in Head and Neck Cancer. | Antioxid Redox Signal | 2018 | https://conductscience.org/library/papers/29113454 | PubMed |
| 28382569 | Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. | Drugs | 2017 | https://conductscience.org/library/papers/28382569 | PubMed |
| 27924064 | Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma. | Oncotarget | 2017 | https://conductscience.org/library/papers/27924064 | PubMed |
| 27110122 | Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27110122 | PubMed |
| 26927178 | Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). | Cancers (Basel) | 2016 | https://conductscience.org/library/papers/26927178 | PubMed |
| 26918562 | Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma. | Head Neck | 2016 | https://conductscience.org/library/papers/26918562 | PubMed |
| 24566736 | Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. | Clin Pharmacokinet | 2014 | https://conductscience.org/library/papers/24566736 | PubMed |
| 24429877 | A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24429877 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL11359 | ChEMBL |
| ERLOTINIB | CHEMBL553 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL553 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17538162
GET https://conductscience.org/api/papers/v1/17538162/cited_by?page=2